Flowable Hemostats Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Flowable Hemostats Market Trends and Insights

Growing Surgical Procedure Volume Driven by Aging Populations

People aged 65 years and older are projected to reach 1.6 billion by 2050, doubling from 2025 levels.^{[1]United Nations, “World Population Ageing 2023,” UN.ORG} That demographic surge drives higher demand for joint replacements, cardiovascular revascularizations, and oncologic resections, three categories that collectively account for the majority of flowable agent use. Asian nations feel the sharpest pressure; Japan’s median age exceeded 49 in 2025, while China had more than 280 million citizens aged 60 or older. Orthopedic trauma in elderly patients often involves anticoagulant therapy, elevating bleeding risk and prompting routine use of gelatin-thrombin matrices. European health systems expanded day-surgery capacity, adding 1,200 ambulatory operating rooms in Germany between 2024 and 2025 to manage patient throughput. Delayed hemostasis extends anesthesia time and lifts per-case costs by USD 500–800, making effective flowable products a financial imperative for procurement committees.

Rising Adoption of Minimally Invasive Surgeries Requiring Effective Hemostasis

Minimally invasive approaches reached 48% of elective general and gynecologic cases in the United States by 2025.^{[2]Centers for Medicare & Medicaid Services, “Hospital Outpatient Prospective Payment System,” CMS.GOV} Laparoscopic and robotic methods limit surgeons’ ability to apply manual pressure, so flowable Hemostats are deployed through small trocars to quickly seal vascular pedicles. Robotic prostatectomy and nephrectomy volumes climbed 12% year-over-year in 2025, each relying on gelatin-based or synthetic polymer matrices that conform to irregular sites. Off-pump coronary bypass surgeries reported 22% lower transfusion requirements when fibrin-collagen combination agents were used, saving USD 1,200 in blood products per case. The FDA cleared Johnson & Johnson’s TRUFILL n-BCA liquid embolic in December 2025, underscoring regulatory support for innovative hemostatic formats tailored to minimally invasive settings. Ambulatory centers leverage pre-loaded syringes to reduce turnover time by up to 10 minutes, enabling an extra daily case.

Favorable Reimbursement Frameworks and Quick Regulatory Clearances in Major Markets

The dedicated U.S. reimbursement code C1849, effective January 2025, reimburses USD 180–220 per absorbable hemostat used in inpatient orthopedic and cardiovascular procedures. Utilization climbed 15% within six months of launch as hospitals no longer absorbed full device cost. In the European Union, Medical Device Regulation Class III reviews for flowable hemostats take 18–24 months, several months faster than for many implantable devices due to lower systemic risk. Baxter renewed its CE Mark for Hemopatch, with expanded pediatric cardiac indications, in April 2025, following a 96.7% success rate at 4 minutes. Japan’s Sakigake pathway cut review times in half for combination products, lifting early-market access for regional innovators.

Increasing Prevalence of Bleeding Disorders and Anticoagulant Usage

Direct oral anticoagulant prescriptions in the United States surpassed 35 million during 2025, up 9% year over year.^{[3]Centers for Disease Control and Prevention, “Anticoagulation Therapy,” CDC.GOV} These agents prolong intraoperative bleeding time, prompting surgeons to use gelatin-thrombin or fibrin sealants that achieve hemostasis within a 5-minute window. Teleflex’s QuikClot Control+ showed 98.7% success in anticoagulated trauma patients after its March 2025 clearance. Elective surgeries in hemophilia and von Willebrand cohorts are also increasing as prophylactic therapies improve baseline coagulation, yet still require adjunctive mechanical-plus-biologic matrices. Each avoided red-blood-cell transfusion saves about USD 250 and reduces average length of stay by nearly two days, reinforcing economic value.

High Product Cost and Limited Reimbursement in Price-Sensitive Regions

With unit prices ranging from USD 150 to USD 300, many flowable agents exceed surgical consumable budgets in India, Brazil, and South Africa, where allocations average USD 80–120 per case. India’s Ayushman Bharat scheme lacks dedicated hemostat reimbursement, so public hospitals default to oxidized cellulose products that take three times longer to work. Brazil’s SUS flat reimbursement of USD 1,200 for elective orthopedic cases squeezes margins, keeping adoption below 15% in state facilities. Volume-based tenders can trim prices São Paulo hospitals obtained gelatin agents at USD 95 in 2025, but usage remains limited to high-risk surgeries. Import tariffs compound challenges; South Africa’s 15% medical-device duty raises landed prices, creating opportunities for local polysaccharide suppliers offering products at USD 60 per unit.

Stringent Storage and Handling Requirements Impacting Shelf Life

Conventional gelatin-thrombin matrices require refrigeration at 2–8 °C and must be mixed immediately before use, adding two to three minutes of OR time and generating waste when prepared syringes expire within two hours. Hot climates drive higher spoilage; Baxter reported 12–18% product loss in regions where ambient temperatures exceed 30 °C for much of the year. The firm’s 2025 room-temperature Hemopatch reformulation sidesteps cold-chain costs, but many competing collagen-fibrinogen patches still demand frozen storage and lengthy thaw times. Regulators now require rigorous prion and endotoxin testing on animal-derived gelatins, adding as much as USD 300,000 to new submissions.

Segment Analysis

By Product Type: Synthetic Polymers Gain Ground Despite Gelatin Dominance

The flowable hemostats market, by gelatin-based products, accounted for 46.23% of global revenue. Collagen variants provide surgeons with greater tensile strength along suture lines. Synthetic polymer agents represented a smaller base yet advanced at a 6.8% CAGR, propelled by demand for animal-free materials that deliver rapid hemostasis even in irrigated fields. Combination and hybrid matrices are the fastest-growing subset, forecast to outpace the overall flowable hemostats market CAGR through 2031. 

Surgeon preference is shifting toward multi-mechanism formats that couple mechanical scaffolds with biologic or mineral procoagulants. Johnson & Johnson’s ETHIZIA patch achieved 80% hemostasis at 30 seconds, six times faster than older collagen-fibrinogen benchmarks, illustrating performance gains that justify premium pricing. Yet cost-conscious hospitals still rely on gelatin products priced at USD 120–180 per unit. Supply-chain volatility from bovine sources, highlighted by 2024 BSE outbreaks, underscores the strategic value of synthetic platforms that avoid animal raw materials altogether.

Note: Segment shares of all individual segments available upon report purchase

By Application: Neurological Surgery Outpaces Cardiovascular Growth

Cardiovascular procedures accounted for 31.82% of the flowable hemostats market revenue in 2025, reflecting the high bleeding risk inherent to bypass grafts and valve replacements. Gelatin-thrombin matrices cut transfusion rates by 22% in off-pump CABG cases, saving USD 1,200 per patient. Neurological surgery, while smaller in absolute terms, is projected to rise 9.87% annually through 2031 as agents that respect delicate cortical tissue gain broader adoption. 

Johnson & Johnson secured FDA approval for TRUFILL n-BCA in December 2025, opening the door for liquid embolics specifically designed for intracranial bleeding. Orthopedic and trauma rely on collagen fibers that activate platelet adhesion within cancellous bone. General and abdominal surgeries account for 18%, with flowable products used to reinforce hepatic and colorectal anastomoses. Plastic, reconstructive, and other specialty fields take the remainder, expanding at mid-single-digit rates as ambulatory centers diversify case mixes.

By End User: ASCs Leverage Workflow Efficiency

Hospitals retained 57.03% of 2025 unit volume, driven by complex cardiovascular and neuro cases that require multiple SKUs for varied bleeding scenarios. Group purchasing organizations are narrowing formularies to two or three suppliers to reduce inventory complexity, reinforcing scale advantages for market leaders. 

Ambulatory surgical centers are growing at an 8.42% CAGR in the flowable hemostats market. Ready-to-use syringes that can be stored at room temperature align with ASC staffing models by eliminating reconstitution delays. Specialty clinics, including orthopedic surgery and catheterization labs, account for about 8% of usage and favor single-step products that fit tight procedure windows. Channel migration toward outpatient settings rewards manufacturers able to supply ambient-stable, multi-indication lines in flexible pack sizes.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America accounted for 36.51% of the flowable hemostats market revenue in 2025, with U.S. facilities accounting for 85% of regional demand following CMS's introduction of reimbursement code C1849. Canada gained momentum as Ontario and Quebec added hemostat coverage, expanding the addressable case base by 12%. Baxter renewed Hemopatch’s CE Mark in April 2025, extending indications into pediatric cardiac surgery after demonstrating a 96.7% four-minute hemostasis rate. 

Asia-Pacific is the fastest-growing region, advancing at a 10.45% CAGR, driven by aggressive capacity additions. China built 2,800 tertiary hospitals between 2024 and 2026, many of which were fitted with hybrid ORs that require versatile hemostats. Japan’s Sakigake designation halved review times for novel collagen-thrombin matrices, supporting quick market entry for domestic innovators. India’s growth is constrained by reimbursement gaps, although private chains are adopting premium agents for high-risk cardiovascular cases. Middle East & Africa and South America combined contribute roughly 8%, with adoption limited by tariff and cold-chain hurdles that favor low-cost polysaccharide alternatives.